Listen & Watch

  1. LNPs & Beyond: Opportunities In RNA Delivery 10/6/2022

    The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the importance of mRNA/RNA therapeutics. For those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening their applicability, durability, and effectiveness.

  2. Cell & Gene Live Audience Q&A 9/16/2022

    During the hour, audience members submitted their questions for our panelists. To no surprise, they asked thoughtful, solid questions on everything from transecting cells with multiple RNA and the challenges associated with chronic dosing of mRNA therapeutics to the regulatory challenges around mRNA cell therapies.

  3. The Not-So-New Challenges Of mRNA Delivery 9/16/2022

    Walter Strapps, Ph.D., CEO of Carver Biosciences states that when it comes to mRNA, the challenges associated with its delivery are anything but new. Indeed, Strapps explains that challenges have existed essentially since the dawn of nucleotide therapeutics in general. “There is a joke within the oligo nucleotide field similar to the real estate industry in that in real estate it’s location, location, location; for all nucleotides it's delivery, delivery, delivery,” says Strapps.

  4. Innovations In mRNA Delivery 9/16/2022

    Learn about the significant history of the work that made mRNA therapeutics and vaccines possible, the broader problem with mRNA therapeutics, and the innovations on the horizon.

  5. The Cell As The Delivery Vehicle 9/16/2022

    Dr. Murat Kalayoglu, CEO, Cartesian Therapeutics explains that Cartesian ensures that the cells it administers, and therefore the RNA therapeutics that is administers, meet all the specifications the company sets forth in advance. Part of those specifications ensures that there are a certain number of cells that are indeed capable of expressing the RNA into the relevant protein and at certain levels. He explains that they have solved the problem before ever infusing the RNA therapeutic directly into the body, and therefore, the class of therapies Cartesian develops are referred to as RNA cell therapy to distinguish them from conventional RNA therapies, where the RNA is either introduced directly or through nanoparticle.

  6. The Wider Use Of mRNA To Treat Various Forms Of Cancer & Autoimmune Diseases 9/16/2022

    Each of the diseases discussed are going to be different in the way that it manifests, and the target cell arguably is going to be different as well. Strapps and Kalayoglu break it down disease by disease.

  7. Advancements In Targeted mRNA Delivery 5/26/2022

    mRNA has broad potential as a therapeutic. The clinical translation of mRNA therapeutics has been made possible through advances in the design of mRNA manufacturing and intracellular delivery methods. However, broad application of mRNA is still limited by the need for improved delivery systems.

  8. CMC, Scale Up, & The Road To mRNA Regulatory Approval 3/16/2022

    Check out part two of our Bioprocess Online Live series on mRNA manufacturing challenges and opportunities. The panel discussion features Dr. Akhilesh Bhambhani, Sr. Director, Biologics Drug Product Development at Ultragenyx Pharmaceuticals and Roberta Duncan, VP and mRNA Program Lead at Seqirus. These two experts discuss some of the most critical steps to mRNA vaccine and therapeutic commercialization, including CMC, scale-up, tech transfer, and regulatory strategy.